Cite
Gorodnova TV, Sokolenko AP, Kotiv KB, et al. Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin. Hered Cancer Clin Pract. 2021;19(1):14doi: 10.1186/s13053-021-00173-2.
Gorodnova, T. V., Sokolenko, A. P., Kotiv, K. B., Sokolova, T. N., Ivantsov, A. O., Guseynov, K. D., Nekrasova, E. A., Smirnova, O. A., Berlev, I. V., & Imyanitov, E. N. (2021). Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin. Hereditary cancer in clinical practice, 19(1), 14. https://doi.org/10.1186/s13053-021-00173-2
Gorodnova, Tatiana V, et al. "Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin." Hereditary cancer in clinical practice vol. 19,1 (2021): 14. doi: https://doi.org/10.1186/s13053-021-00173-2
Gorodnova TV, Sokolenko AP, Kotiv KB, Sokolova TN, Ivantsov AO, Guseynov KD, Nekrasova EA, Smirnova OA, Berlev IV, Imyanitov EN. Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin. Hered Cancer Clin Pract. 2021 Feb 03;19(1):14. doi: 10.1186/s13053-021-00173-2. PMID: 33536037; PMCID: PMC7860626.
Copy
Download .nbib